Why age specifically strengthens the case for PGT-A
Chromosomal abnormality rates in embryos rise substantially with maternal age — for patients in their late 30s and 40s specifically, PGT-A can meaningfully reduce the chance of transferring a chromosomally abnormal embryo, potentially reducing miscarriage risk and failed transfers.
What the evidence shows, and its limits
Multiple studies support reduced miscarriage rates and improved per-transfer success when using PGT-A-selected embryos in this age group — though the evidence is less clearly favorable for reducing overall time-to-pregnancy in younger patients with better baseline embryo quality.
The mosaic embryo consideration
Some embryos classified as "mosaic" (a mix of normal and abnormal cells) have resulted in healthy births when transferred — a genuinely evolving area of the evidence worth discussing specifically with your reproductive endocrinologist rather than treating any PGT-A result as absolute.
PGT content on this site is scoped strictly to chromosomal screening (PGT-A) and known genetic disease screening (PGT-M/PGT-SR) — not sex selection or non-medical trait selection.
See colombianivf.com for PGT-A availability and evidence-based counseling from Colombia-based providers.
The Takeaway
PGT-A's evidence case is genuinely strongest for advanced maternal age specifically — discuss whether it fits your specific age and situation with your reproductive endocrinologist, rather than assuming it's universally beneficial.